H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of myositis based on positive Phase 2 results. The firm says efgartigimod could potentially be the first targeted treatment for myositis. Given cost and ease of use, it expects efgartigimod would be used ahead of cell therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: